<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04622397</url>
  </required_header>
  <id_info>
    <org_study_id>tranexamic acid in scoliosis</org_study_id>
    <nct_id>NCT04622397</nct_id>
  </id_info>
  <brief_title>Local Subfascial and Intramuscular Tranexamic Acid Administration in Pediatric Patient Undergoing Scoliosis Surgery, Double Blind Randomized Control Trial</brief_title>
  <official_title>Local Subfascial and Intramuscular Tranexamic Acid Administration in Pediatric Patient Undergoing Scoliosis Surgery, Double Blind Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesized that local administration of tranexamic acid will minimize blood loss and&#xD;
      blood product administration in pediatric patient undergoing scoliosis surgery&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spine surgery in paediatrics is frequently associated with substantial blood loss.&#xD;
&#xD;
      Blood product adminestration in children has many complications that are not fully known.&#xD;
&#xD;
      There are many modalities currently available to reduce blood loss in pediatric patients.&#xD;
&#xD;
      Tranexamic acid is tissue plasminogen activator inhibitor that reduce perioperative blood&#xD;
      loss.&#xD;
&#xD;
      To date, no studies have investigated effect of local administration of tranexamic acid in&#xD;
      pediatric population undergoing scoliosis surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 10, 2021</start_date>
  <completion_date type="Anticipated">December 29, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 29, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized comparative study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Care Provider)</masking>
    <masking_description>surgeon will be blinded to type of injection</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Intraperative blood loss in both groups</measure>
    <time_frame>period of surgery(1-2 hours)</time_frame>
    <description>amount of blood/kg(ml/kg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>post-operative blood loss</measure>
    <time_frame>24 hours</time_frame>
    <description>amount of blood in drain after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood product admenestration</measure>
    <time_frame>duration of procedure(1-2 hours)</time_frame>
    <description>units of blood given during surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Blood Loss, Surgical</condition>
  <condition>Scoliosis</condition>
  <arm_group>
    <arm_group_label>Group T (tranexamic acid),n=15</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group T: tranexamic acid 10 mg/kg will be injected locally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group S (saline) (n=15)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group S saline will be injected</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid injection</intervention_name>
    <description>Local subfascial and intramuscular infiltration will be performed by surgeon at levels of fixation prior to skine incision</description>
    <arm_group_label>Group T (tranexamic acid),n=15</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Local subfascial and intramuscular infiltration will be performed by surgeon at levels of fixation prior to skine incision</description>
    <arm_group_label>Group S (saline) (n=15)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children aged 2-12 years&#xD;
&#xD;
          -  Of both sexes&#xD;
&#xD;
          -  American society of anesthesiologist (ASA) physical status classification class I&#xD;
&#xD;
          -  Undergoing general anesthesia for scoliosis surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Parents' refusal of regional block&#xD;
&#xD;
          -  Known allergy to tranexamic acid&#xD;
&#xD;
          -  Bleeding disorders (INR &gt;1.4,Platelet count&lt; 75000)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mina Adolf Helmy, MD</last_name>
    <phone>2001275716942</phone>
    <email>dr_mina20002010@yahoo.com</email>
  </overall_contact>
  <reference>
    <citation>Bible JE, Mirza M, Knaub MA. Blood-loss Management in Spine Surgery. J Am Acad Orthop Surg. 2018 Jan 15;26(2):35-44. doi: 10.5435/JAAOS-D-16-00184. Review.</citation>
    <PMID>29303921</PMID>
  </reference>
  <reference>
    <citation>Goobie SM. A blood transfusion can save a child's life or threaten it. Paediatr Anaesth. 2015 Dec;25(12):1182-3. doi: 10.1111/pan.12816.</citation>
    <PMID>26507915</PMID>
  </reference>
  <reference>
    <citation>Mikhail C, Pennington Z, Arnold PM, Brodke DS, Chapman JR, Chutkan N, Daubs MD, DeVine JG, Fehlings MG, Gelb DE, Ghobrial GM, Harrop JS, Hoelscher C, Jiang F, Knightly JJ, Kwon BK, Mroz TE, Nassr A, Riew KD, Sekhon LH, Smith JS, Traynelis VC, Wang JC, Weber MH, Wilson JR, Witiw CD, Sciubba DM, Cho SK. Minimizing Blood Loss in Spine Surgery. Global Spine J. 2020 Jan;10(1 Suppl):71S-83S. doi: 10.1177/2192568219868475. Epub 2020 Jan 6.</citation>
    <PMID>31934525</PMID>
  </reference>
  <reference>
    <citation>Slaughter TF, Greenberg CS. Antifibrinolytic drugs and perioperative hemostasis. Am J Hematol. 1997 Sep;56(1):32-6. Review.</citation>
    <PMID>9298865</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 4, 2020</study_first_submitted>
  <study_first_submitted_qc>November 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Mina Adolf Helmy</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scoliosis</mesh_term>
    <mesh_term>Blood Loss, Surgical</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

